Bionano Genomics Past Earnings Performance

Past criteria checks 0/6

Bionano Genomics's earnings have been declining at an average annual rate of -40.1%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 31.5% per year.

Key information

-40.1%

Earnings growth rate

33.9%

EPS growth rate

Life Sciences Industry Growth36.9%
Revenue growth rate31.5%
Return on equity-277.9%
Net Margin-407.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bionano Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0A4K Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2433-1367133
30 Jun 2437-2047342
31 Mar 2437-2279050
31 Dec 2336-2329554
30 Sep 2334-2279956
30 Jun 2332-1479755
31 Mar 2330-1409152
31 Dec 2228-1338649
30 Sep 2226-1178144
30 Jun 2223-1067638
31 Mar 2221-926830
31 Dec 2118-725722
30 Sep 2116-614716
30 Jun 2113-514012
31 Mar 2111-413210
31 Dec 209-413010
30 Sep 207-372810
30 Jun 208-332310
31 Mar 209-322310
31 Dec 1910-30209
30 Sep 1911-281810
30 Jun 1911-271710
31 Mar 1912-23169
31 Dec 1812-18149
30 Sep 1811-18139
30 Jun 1811-181310
31 Mar 1810-221411
31 Dec 1710-231412
31 Dec 167-191311

Quality Earnings: 0A4K is currently unprofitable.

Growing Profit Margin: 0A4K is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0A4K is unprofitable, and losses have increased over the past 5 years at a rate of 40.1% per year.

Accelerating Growth: Unable to compare 0A4K's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0A4K is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).


Return on Equity

High ROE: 0A4K has a negative Return on Equity (-277.86%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 15:08
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bionano Genomics, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Constantine DavidesD. Boral Capital LLC.
Jeffrey CohenLadenburg Thalmann & Company